Neoadjuvant versus Perioperative Chemotherapy for Resectable Colorectal Liver Metastases: An International Multicentre Propensity-score Matched Analysis
نویسندگان
چکیده
Background: There is still uncertainty regarding the role of perioperative chemotherapy (CTx) in context resectable colorectal liver metastases (CRLM). The aim this study was to assess differences long-term oncologic outcomes patients with CRLM who had neoadjuvant CTx only versus those received combined adjuvant therapy (perioperative CTx). Methods: International multicentre retrospective analysis undergoing resection between 2010 and 2015. Patients were divided into two groups according whether they (maximum 6 cycles) CTx. Then compared before after using a propensity-score matching (PSM) analysis. main post-operative complications, recurrence-free survival (RFS) overall (OS). Results: Out 967 treated, 252 included analysis, median follow-up 45 months. unmatched comparison revealed bias towards presenting lower Clinical Risk Score (p = 0.010) GAME score 0.030), as well increased postoperative complications ≥ Clavien-Dindo III (20.9% vs 8%, p 0.002). After PSM (n 184 patients) comparable regards baseline characteristics, model exhibiting good discrimination calibration. matched showed that group presented significantly prolonged RFS (HR 0.53, 95%CI 0.37-0.76, 0.007) OS 0.58, 0.38-0.87, (Fig. 1). Conclusion: When are able tolerate additional CTx, strategy demonstrates only.
منابع مشابه
The role of neoadjuvant chemotherapy for resectable colorectal liver metastases: a systematic review and meta-analysis
Neoadjuvant chemotherapy is being increasingly accepted as an effective treatment of resectable colorectal liver metastases (CRLM), but it may also damage the hepatic parenchyma. We performed a meta-analysis to compare the outcomes of patients who received neoadjuvant chemotherapy (NEO) prior to hepatic resection with hepatic resection without neoadjuvant chemotherapy (SG). Eligible trials were...
متن کاملEvaluation of resectability after neoadjuvant chemotherapy for primary non-resectable colorectal liver metastases: A multicenter study.
BACKGROUND/AIM The Kyushu Study Group of Clinical Cancer (KSCC) previously reported the safety and efficacy of neoadjuvant chemotherapy with mFOLFOX6 + bevacizumab for H2/H3 liver metastases of colorectal cancer. The aim of the current study was to evaluate the resectability of these metastases before and after chemotherapy as determined by independent liver surgeons. METHODS Between May 2008...
متن کاملEffect of Neoadjuvant Chemotherapy in Patients with Resectable Colorectal Liver Metastases
BACKGROUND Whether patients with resectable colorectal liver metastases (CRLM) receive survival benefit from neoadjuvant chemotherapy remains controversial. METHODS We retrospectively analyzed 466 patients with resectable CRLM between 2000 and 2010. Patient characteristics and survival data were recorded. RESULTS The patients were divided into one group with neoadjuvant chemotherapy (group ...
متن کاملIs neoadjuvant chemotherapy necessary for patients with initially resectable colorectal liver metastases in the era of effective chemotherapy?
BACKGROUNDS/AIMS Hepatic resection has only guaranteed long-term survival in patients with colorectal liver metastasis (CRLM) even in the era of effective chemotherapy. The definite role of neoadjuvant chemotherapy (NCT) is to improve outcomes of unresectable CRLMs, but it its role has not been defined for initially resectable CRLMs (IR-CRLMs). METHODS We reviewed the medical records of 226 p...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Hpb
سال: 2021
ISSN: ['1365-182X', '1477-2574']
DOI: https://doi.org/10.1016/j.hpb.2021.08.003